Pharmacoeconomic review report Empagliflozin (Jardiance)
Empagliflozin (Jardiance) is a once-daily oral antidiabetic drug belonging to the sodium glucose cotransporter-2 (SGLT-2) inhibitor class. It promotes urinary glucose excretion. This review by the CADTH Common Drug Review (CDR) will focus on the following indication: 1. For adults with type 2 diabet...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
CADTH
2015.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820270006719 |
